Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Salarius Pharmaceuticals ( (SLRX) ) has issued an update.
On December 31, 2025, Salarius Pharmaceuticals, Inc. disclosed that it had received notice from Nasdaq that the company was no longer in compliance with the exchange’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive business days. Because Salarius conducted a reverse stock split within the prior year and remains under a Mandatory Panel Monitor, it is not eligible for the standard 180-day grace period to cure the deficiency, and, absent an appeal by January 7, 2026, its stock is scheduled for suspension and delisting from The Nasdaq Capital Market effective January 9, 2026, followed by deregistration from Nasdaq. The company said it intends to appeal the delisting determination to a Nasdaq Hearings Panel, which would temporarily stay the suspension and delisting process while Salarius presents a plan to regain compliance, although there is no assurance that the panel will rule in favor of maintaining the listing, leaving shareholders exposed to the risk of the stock moving to a less liquid trading venue.
The most recent analyst rating on (SLRX) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Salarius Pharmaceuticals stock, see the SLRX Stock Forecast page.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn) and very bearish technicals (price far below major moving averages with negative MACD). Corporate events provide some offset via financing, a merger, and Nasdaq compliance progress, but valuation metrics offer limited support given negative earnings and no dividend data.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a biotechnology company whose common stock is listed on The Nasdaq Capital Market, giving it access to public equity markets and visibility among life-science investors.
Average Trading Volume: 1,842,719
Technical Sentiment Signal: Sell
Current Market Cap: $4.14M
Learn more about SLRX stock on TipRanks’ Stock Analysis page.